Medizin
Refine
Year of publication
- 2018 (472) (remove)
Document Type
- Article (439)
- Contribution to a Periodical (9)
- Doctoral Thesis (9)
- Part of Periodical (9)
- Book (3)
- Conference Proceeding (1)
- Preprint (1)
- Report (1)
Has Fulltext
- yes (472)
Is part of the Bibliography
- no (472)
Keywords
- breast cancer (15)
- Mammakarzinom (10)
- Behandlung (8)
- inflammation (7)
- CDK4/6 (6)
- Metastasen (6)
- Neuroscience (6)
- PD1/PDL1 (6)
- Studien (6)
- treatment (6)
- Blood (5)
- Research article (5)
- cancer (5)
- metastases (5)
- Biomarker (4)
- Cirrhosis (4)
- Depression (4)
- Germany (4)
- Hemorrhage (4)
- Inflammation (4)
- Prävention (4)
- Risiko (4)
- Schizophrenia (4)
- diagnosis (4)
- mutual information (4)
- pain (4)
- prevention (4)
- reactive oxygen species (4)
- risk (4)
- trials (4)
- Biomarkers (3)
- Breast cancer (3)
- Cancer (3)
- Cell staining (3)
- EEG microstates (3)
- Flow cytometry (3)
- HIV (3)
- Hepatocellular carcinoma (3)
- Liver diseases (3)
- Mental health and psychiatry (3)
- Morbidity (3)
- Neonates (3)
- Obesity (3)
- Prognosis (3)
- Stem cells (3)
- aging (3)
- autophagy (3)
- chemotherapy (3)
- entropy (3)
- glioblastoma (3)
- information theory (3)
- macrophage (3)
- metastasis (3)
- mitochondria (3)
- regeneration (3)
- sphingolipids (3)
- Alcohol consumption (2)
- Antiretroviral therapy (2)
- Atherosclerosis (2)
- Atrial fibrillation (2)
- Autism (2)
- Autism spectrum disorder (2)
- Autophagy (2)
- BRAF (2)
- Blood pressure (2)
- Brain metastasis (2)
- Brustkrebs (2)
- COPD (2)
- CTGF (2)
- Cardiac magnetic resonance (2)
- Cardiovascular diseases (2)
- Cardiovascular magnetic resonance (2)
- Cell therapy (2)
- Citation analysis (2)
- Complications (2)
- Consensus (2)
- Crystal structure (2)
- Cytoskeleton (2)
- DAA (2)
- Death rates (2)
- Deutschland (2)
- Diabetes (2)
- Diagnose (2)
- Diagnostic markers (2)
- Diagnostic medicine (2)
- Diagnostik (2)
- Emotions (2)
- Etiology (2)
- Evaluation (2)
- Everolimus (2)
- Exercise (2)
- Eyes (2)
- Face (2)
- Fistula (2)
- Früherkennung (2)
- Galaktografie (2)
- Galaktomosynthese (2)
- General practice (2)
- Genome-wide association studies (2)
- Guidelines (2)
- HCC (2)
- Hematology (2)
- Immunology (2)
- Kidney transplantation (2)
- Knees (2)
- Liver fibrosis (2)
- Lokalrezidiv (2)
- Long non-coding RNAs (2)
- MRI (2)
- MRT (2)
- Mamma (2)
- Markovianity (2)
- Medical education (2)
- MicroRNAs (2)
- Mixed methods (2)
- Morphometry (2)
- Mortality (2)
- Multimorbidity (2)
- Multiple chronic conditions (2)
- Musculoskeletal system (2)
- Nachsorge (2)
- Nerve fibers (2)
- Next-generation sequencing (2)
- Non-small cell lung cancer (2)
- Oncology (2)
- Operation/Chirurgie (2)
- PCR (2)
- PD1/ PDL1 (2)
- Palliative care [MeSH] (2)
- Patients (2)
- Percutaneous coronary intervention (2)
- Periodontitis (2)
- Polypharmacy (2)
- Primary care (2)
- Prognosefaktoren (2)
- Prostate cancer (2)
- Prädiktivfaktoren (2)
- Pulmonary hypertension (2)
- Reaction time (2)
- Richtlinie (2)
- Scientists (2)
- Sepsis (2)
- Stroke (2)
- Surgical and invasive medical procedures (2)
- Surgical oncology (2)
- Survival (2)
- Sweden (2)
- Teeth (2)
- Tomosynthese (2)
- Trauma (2)
- Ultraschall (2)
- Validation (2)
- Viral load (2)
- Vitamin D (2)
- Vitamin D deficiency (2)
- acute kidney injury (2)
- angiogenesis (2)
- antioxidants (2)
- ataxia telangiectasia (2)
- atherosclerosis (2)
- attention (2)
- bioinformatics (2)
- breast (2)
- cardiac surgery (2)
- catheter ablation (2)
- ceramides (2)
- child (2)
- chronic kidney disease (2)
- connectivity (2)
- cytokines (2)
- data science (2)
- development (2)
- endothelial cells (2)
- epilepsy (2)
- follow‑up (2)
- forensic entomology (2)
- galactography (2)
- galactomosynthesis (2)
- guideline (2)
- hedgehog signaling (2)
- hepatitis C virus (2)
- human (2)
- hyperglycemia (2)
- hypoxia (2)
- imaging (2)
- immunotherapy (2)
- innate immunity (2)
- interleukin-4 (2)
- liver injury (2)
- local recurrence (2)
- lyme disease (2)
- matrix (2)
- medical students (2)
- mesenchymal stromal/stem cells (2)
- metabolism (2)
- miRNA (2)
- microRNA (2)
- minimalinvasive Biopsie (2)
- minimally invasive biopsies (2)
- neoadjuvant chemotherapy (2)
- neoadjuvante Chemotherapie (2)
- next generation sequencing (NGS) (2)
- obesity (2)
- paclitaxel (2)
- predictive factors (2)
- pregnancy (2)
- primary immunodeficiency (2)
- prognostic factors (2)
- psoriasis (2)
- radiation (2)
- rapamycin (2)
- reproducibility (2)
- resistance (2)
- safety (2)
- schizophrenia (2)
- screening (2)
- seizure (2)
- sphingosine 1-phosphate (2)
- spreadsheet (2)
- stationarity (2)
- studies (2)
- surgery (2)
- tobacco prevention (2)
- tomosynthesis (2)
- treatment/therapy (2)
- ultrasound (2)
- vector (2)
- vemurafenib (2)
- workflow (2)
- (surface) partial differential equations (1)
- 1,2-dichloroethane (1)
- 1,25-Dihydroxyvitamin D (1)
- 16p11.2 (1)
- 2-deoxyglucose (2-DG) (1)
- 3D spatio-temporal resolved mathematical models (1)
- 4-FA (1)
- A375 human melanoma cells (1)
- A549 (1)
- ACE-inhibitor (1)
- ACURATE neo (1)
- ADHD (1)
- AIDS (1)
- AKI (1)
- ALK gene (1)
- ALK-rearranged NSCLC (1)
- ARA (1)
- ARFI (1)
- ASO (1)
- ATP-citrate lyase (1)
- Abatacept (1)
- Acoustics (1)
- Activities of daily living (1)
- Acute bronchitis (1)
- Acute cough (1)
- Acute lymphocytic leukaemia (1)
- Acute myeloid leukemia (1)
- Adenylyl cyclase (1)
- Adipose-derived mesenchymal stem cells (1)
- Adults (1)
- Aedes aegypti (1)
- Aedes albopictus (1)
- Age (1)
- Age groups (1)
- Aggressive periodontitis (1)
- Akaike information criterion (AIC) (1)
- Aliphatic halogenated hydrocarbons (1)
- Alleles (1)
- Allergic asthma (1)
- Allgemeinmedizin (1)
- Alveolar ridge augmentation (1)
- Ambroxol (1)
- Anatomie (1)
- Anatomie und Histologie (1)
- Andexanet alpha (1)
- Angioedema (1)
- Angiogenesis (1)
- Angioplasty (1)
- Animal wings (1)
- Anomalie <Medizin> (1)
- Antibiotics (1)
- Antibodies (1)
- Antibody-mediated rejection (1)
- Anticoagulant therapy (1)
- Antiretrovirals (1)
- Antirheumatic agents (1)
- Antithrombotic therapy (1)
- Antiviral agents (1)
- Antiviral therapy (1)
- Apixaban (1)
- Apoptosis (1)
- Aquaporins (1)
- Arms (1)
- Ascites (1)
- Aspergillus (1)
- Asphyxia (1)
- Atrial appendage occlusion (1)
- Attention (1)
- Attention-deficit / hyperactivity disorder (1)
- Attitude (1)
- Aurora A (1)
- Austria (1)
- Auto transfusion (1)
- Autoimmunity (1)
- Autopsy (1)
- Axons (1)
- Azathioprine (1)
- B cell subpopulations (1)
- B cells (1)
- B-cell immunology (1)
- B-cell lymphoma (1)
- BATF3 (1)
- BCG-Therapie (1)
- BCR signaling (1)
- BIAM-switch (1)
- BMC (1)
- BPD (1)
- BRCA1 (1)
- BRCA2 (1)
- BTK (1)
- Babesia divergens (1)
- Babesia microti (1)
- Bacterial meningitis (1)
- Bacterial pathogens (1)
- Bayesian inference (1)
- Behavioral analysis (1)
- Benefit (1)
- Best practice (1)
- Bibliometrics (1)
- Bidirectional genes (1)
- Big Data (1)
- Big data (1)
- Big five (1)
- Biofluids (1)
- Bioinformatics (1)
- Biological (1)
- Biological invasion (1)
- Biomechanical analysis (1)
- Biophysical models (1)
- Biopsy (1)
- Biosynthetic mesh (1)
- Bipolar disorder (1)
- Birth weight (1)
- Blasenkarzinom (1)
- Blended learning curriculum · (1)
- Blended-Learning-Curriculum (1)
- Blood cells (1)
- Blood groups (1)
- Blood-brain barrier (1)
- Bloodstream infections (1)
- Blurred vision (1)
- Blutgefäß (1)
- Bone defect (1)
- Bone marrow cells (1)
- Bone marrow fibrosis (1)
- Bone marrow mononuclear cells (1)
- Bone marrow-derived mesenchymal stem cells (1)
- Bone tissue engineering (1)
- Borrelia (1)
- Borrelia burgdorferi (1)
- Borrelia miyamotoi (1)
- Bradykinin (1)
- Brain anatomy (1)
- Brain damage (1)
- Brain ischemia (1)
- Breast tumors (1)
- Bright light therapy (1)
- Bronchial inflammation (1)
- Bronchitis severity scale (1)
- Bronchopulmonary dysplasia (1)
- Burden of disease (1)
- Bypass liner (1)
- C-reactive protein (1)
- C. elegans (1)
- C1 inhibitor (1)
- C1-inhibitor (1)
- C5 acylcarnitine (1)
- CCL2 (1)
- CCN2 (1)
- CD3/19 depletion (1)
- CD34 selection (1)
- CD36 (1)
- CD74 (1)
- CDK4/6 inhibitor (1)
- CHRNA10 (1)
- CHRNA7 (1)
- CHRNA9 (1)
- CNS (1)
- CO2-induced forced ventilation (1)
- COI (1)
- COII (1)
- COMT (1)
- COPD course and therapy (1)
- CRE-luciferase (1)
- CRISPR/Cas9 (1)
- CRM1 (1)
- CTX (1)
- Ca2+ imaging (1)
- Caffeine (1)
- Calcium signalling (1)
- Calnexin (1)
- Cancer detection and diagnosis (1)
- Cancer epidemiology (1)
- Cancer treatment (1)
- Carbon tetrachloride (1)
- Cardiac Fibrosis (1)
- Cardiac surgery (1)
- Cardiac surgery patients (1)
- Cardiomyopathy (1)
- Cardiovascular biology (1)
- Cardiovascular disease (1)
- Cardiovascular genetics (1)
- Cell binding (1)
- Cell cultures (1)
- Cell distribution (1)
- Cell membranes (1)
- Cell salvage (1)
- Cell signalling (1)
- Cementation (1)
- Ceramic (1)
- Cerclage (1)
- Cerebral ischemia (1)
- Cerebrospinal fluid (1)
- Certification (1)
- Cesarean section (1)
- Chaperone (1)
- Chemical biology (1)
- Chemical ecology (1)
- Chemobrain (1)
- Chemoembolization (1)
- Chest pain unit (1)
- Chikungunya virus (1)
- Child (1)
- Children (1)
- Chloroform (1)
- Chondrocytes (1)
- Chromatin accessibility (1)
- Chromatin and Epigenetics (1)
- Chronic heart failure (1)
- Chronic periodontiti (1)
- Chronification (1)
- Circadian rhythms and sleep (1)
- Cleanliness level (1)
- Clinical frailty scale (1)
- Clinical genetics (1)
- Clinical outcome (1)
- Clinical psychometry (1)
- Clinical study (1)
- Clinical trials (1)
- Closure (1)
- Co-culture (1)
- Co-morbidity (1)
- Cocaine (1)
- Cognition (1)
- Cognitive neuroscience (1)
- Colon cancer (1)
- Colon capsule endoscopy (1)
- Comparative effectiveness research (1)
- Complement system (1)
- Complementation rate (1)
- Complete heart block (1)
- Complex I (1)
- Complex II (1)
- Complex hernia (1)
- Complex networks (1)
- Complication management (1)
- Connective tissue (1)
- Consortia (1)
- Conventional synthetic disease-modifying antirheumatic drug (1)
- Coronary artery disease (1)
- Coronary intervention (1)
- Credentialing (1)
- Critical bleeding (1)
- Crohn’s disease (1)
- CspZ (1)
- Curriculum (1)
- Cystic fibrosis (1)
- Cytokines (1)
- Cytology (1)
- DAMP (1)
- DLBCL (1)
- DMARDs (biologic) (1)
- DMARDs (synthetic) (1)
- DNA methylation (1)
- DNA mismatch repair (1)
- DNase1-seq (1)
- DOK1 (1)
- DSM (1)
- DTI (1)
- Dabigatran (1)
- Data acquisition (1)
- Data processing (1)
- Data science (1)
- Data visualization (1)
- Decision making (1)
- Deformation (1)
- Dengue (1)
- Dengue fever (1)
- Dengue virus (1)
- Density equalizing mapping (1)
- Dental implants (1)
- Dental phobia (1)
- Dental training (1)
- Dentition (1)
- Dermatomyositis (1)
- Developmental biology (1)
- Diabetes mellitus (1)
- Diagnosis (1)
- Dichloromethane (1)
- Differentiation (1)
- Digital ethics (1)
- Digital rectal examination (1)
- Digital transformation (1)
- Digitale Ethik (1)
- Digitale Transformation (1)
- Dimer (1)
- Dimers (Chemical physics) (1)
- Direct current electrical stimulation (1)
- Disc herniation (1)
- Dissociative seizures (1)
- Distance to water (1)
- Donor Selection (1)
- Dopamine (1)
- Drug discovery (1)
- Drug interactions (1)
- Drug therapy (1)
- Dual therapy (1)
- E/I-Balance (1)
- EGFL7 (1)
- EMT (1)
- ENCODE-DREAM in vivo Transcription Factor binding site prediction challenge (1)
- ERMS (1)
- Early diagnosis (1)
- Early recurrence (1)
- Edoxaban (1)
- Elderly (1)
- Elective caesarean section (1)
- Elevation (1)
- Ellipsoids (1)
- Emotional recognition (1)
- Endocrine cancer (1)
- Endoscopy (1)
- England (1)
- Ensemble learning (1)
- Enterostomy (1)
- Enterostomy closure (1)
- Enterostomy formation (1)
- Environmental chemistry (1)
- Enzyme kinetics (1)
- Enzyme mechanisms (1)
- Epidemiology (1)
- Epidermal growth factor receptor (1)
- Epidural block (1)
- Epigenetics (1)
- Epileptic seizures (1)
- Epithelial cells (1)
- Epstein-Barr virus (1)
- Epstein–Barr virus (1)
- Equipment (1)
- Ergonomics (1)
- Estradiol (1)
- Europe (1)
- European registry for idiopathic pulmonary fibrosis (eurIPFreg) (1)
- Examination questions (1)
- Exosomes (1)
- Experimental models of disease (1)
- Extinction (1)
- Extracellular matrix (1)
- Extracellular matrix proteins (1)
- Extracorporeal purification (1)
- Eye movements (1)
- FAM134B (1)
- FGFR (1)
- FOXO3a (1)
- FTY720 (1)
- FX06 (1)
- Factor analysis (1)
- Fallbeispiele (1)
- Fatiguesyndrom (1)
- Fear conditioning (1)
- FibroScan (1)
- Fibroblasts (1)
- Fibrosis (1)
- Finite Element Method (1)
- Finite Volumes (1)
- Flaps (1)
- Forensics (1)
- Formation dance (1)
- Frailty (1)
- Frühgeburt (1)
- Functional clustering (1)
- G2A (1)
- GABAergic interneurons (1)
- GLI inhibitors (1)
- GPCR (1)
- GSK3α (1)
- GSK3β (1)
- Games (1)
- Gamma-Band Activity (1)
- Gap junctions (1)
- Gastric cancer (1)
- Gastrointestinal cancer (1)
- Gastrointestinal tract (1)
- Gebärmutterhalskrebs (1)
- Gender gap (1)
- Gene Regulation (1)
- Gene expression (1)
- Gene fusion (1)
- Gene microarray analysis (1)
- Gene therapy (1)
- General dental practice (1)
- Generation time (1)
- Geographically weighted regression (GWR) (1)
- German people (1)
- Gestational age (1)
- Glaucoma (1)
- Glioblastoma (1)
- Glycosphingolipids (1)
- Grafts (1)
- Gram negative bacteria (1)
- Greater tuberosity fractures (1)
- Growth factors (1)
- HACA (1)
- HBV reactivation (1)
- HCV treatment (1)
- HER2 c-erbB2 (1)
- HER2-positive (1)
- HER2/neu (1)
- HH (1)
- HIV serodiagnosis (1)
- HIV-1 (1)
- HLA class II (1)
- HLA peptidome (1)
- HMGB1 (1)
- HPV (1)
- HRas (1)
- Haematoma expansion (1)
- Haemostatics (1)
- Hashimoto’s thyroiditis (1)
- Hausarztmangel (1)
- Head injury (1)
- Health care resource utilization (1)
- Health economics (1)
- Health information (1)
- Health risk analysis (1)
- Health-seeking behaviour (1)
- Heart transplantation (1)
- Hedgehog pathway (1)
- Helpline (1)
- Hematocrit value (1)
- Hematopoietic stem cell transplantation (1)
- Hemodynamics (1)
- HepG2 (1)
- Hepatitis B virus (1)
- Hepatitis C (1)
- Hepatitis C virus (1)
- Hepatitis C, Chronic (1)
- Herbalife (1)
- Hereditary breast and ovarian cancer (1)
- HhAntag (1)
- High-intensity interval endurance training (1)
- Hindu Kush Himalayas (1)
- Hip (1)
- Histology (1)
- Histone post-translational modifications (1)
- Homeostasis (1)
- Horner's syndrome (1)
- Horses (1)
- HuR (1)
- Human behaviour (1)
- Human prostate (1)
- Hydroxychloroquine (1)
- Hydroxycut (1)
- Hydroxyurea (1)
- Hypoxia inducible factor (1)
- Hysterektomie-Prävalenz (1)
- IFN (1)
- IL-18BP (1)
- IL-1β (1)
- IL-6 (1)
- IRES translation (1)
- ITGA7 (1)
- IVA interference tandem mass spectrometry (1)
- Iceland (1)
- Idarucizumab (1)
- Idiopathic pulmonary fibrosis (IPF) (1)
- Imaging (1)
- Imaging in LGG (1)
- Immune suppression (1)
- Immunosenescence (1)
- Immunotherapy (1)
- Implementation (1)
- Incisional hernia (1)
- Incomplete colonoscopy (1)
- Indirect-binding (1)
- Induced sputum (1)
- Infectious disease epidemiology (1)
- Inflammatory diseases (1)
- Injuries (1)
- Injury (1)
- Insulin (1)
- Intensive care outcome (1)
- Intensive care units (1)
- Interferon-frei (1)
- Interleukin-6 (1)
- Interspecific competition (1)
- Interstitial lung diseases (ILD) (1)
- Intervertebral disc degeneration (1)
- Intra-abdominal infection (1)
- Intracellular pathogens (1)
- Intracerebral haemorrhage (1)
- Intracranial haemorrhage (1)
- Intracranial hemorrhage (1)
- Intragastric balloon (1)
- Inzidenzkorrektur (1)
- Irregular vaccination (1)
- Italy (1)
- Ivor Lewis esophagectomy (1)
- JNK3 (1)
- Jaw (1)
- Jumping (1)
- KAP (1)
- KDIGO (1)
- Kaisidis plate (1)
- Kidney Transplantation (1)
- Kidney transplant recipients (1)
- Knowledge (1)
- Krebsforschung (1)
- Kupffer cells (1)
- Kynurenine (1)
- LCH (1)
- Labor and delivery (1)
- Lactic acidosis (1)
- Landarztprogramm (1)
- Langerhans cell histiocytosis (1)
- Language (1)
- Laparostomy (1)
- Laterality (1)
- Lebensqualität (1)
- Leberzirrhose (1)
- Lectin affinity plasmapheresis (1)
- Leflunomide (1)
- Legs (1)
- Lernerfolgsmessung (1)
- Lesions (1)
- Leukocyte elastase (1)
- Light sheet fluorescence microscopy (1)
- Linear regression analysis (1)
- Lipidol (1)
- Lipopolysaccharide-binding protein (1)
- Liver cirrhosis (1)
- Liver transplantation (1)
- Livestock (1)
- LncRNA (1)
- Local climate (1)
- Local control (1)
- Locomotor circuit (1)
- Low volume prep (1)
- Low-grade glioma (1)
- Luciferase (1)
- Lumbar spine (1)
- Lung adenocarcinoma (1)
- Lymphom (1)
- Lymphozyt (1)
- Lysosome (1)
- MDR1 (1)
- MEIS2 (1)
- MET (1)
- MOLLI (1)
- MR spectroscopy (1)
- MR-proADM (1)
- MRP4 (1)
- Machine learning (1)
- Macrophages (1)
- Malaria (1)
- Mammalian target of rapamycin (1)
- Marburg virus (1)
- Maternal morbidity (1)
- Maxillary sinus (1)
- Medical communication (1)
- Medical ethics (1)
- Medical hypoxia (1)
- Medical imaging (1)
- Medical risk factors (1)
- Medical traineeship (1)
- Medication Appropriateness Index (1)
- Medication changes (1)
- Medizinische Abbildung (1)
- Medizinische Ausbildung (1)
- Medizinstudierende (1)
- Medizinstudium (1)
- Membrane proteins (1)
- Membrane staining (1)
- Mentor (1)
- Mesangial cells (1)
- Mesh (1)
- Mesh repair (1)
- Messenger RNA (1)
- Metabolic syndrome (1)
- Methotrexate (1)
- Micro RNAs (1)
- Micro-CT (1)
- Microalgae (1)
- Microbial mutation (1)
- Microbiome (1)
- Microsatellite instability (1)
- Middle East respiratory syndrome coronavirus (1)
- Midline laparotomy (1)
- Minimal core of imaging (1)
- Minimal invasive (1)
- Mitochondria (1)
- Mitochondrial ROS (1)
- Mitochondrial disorder (1)
- Mitochondrial proteins (1)
- Mitochondrial respiration (1)
- MitraClip (1)
- Model Organism (1)
- Molecular genetics (1)
- Molecular medicine (1)
- Monocytes and macrophages (1)
- Monolithic crown (1)
- Monte Carlo method (1)
- Morphogenesis (1)
- Mortalitätskorrektur (1)
- Motor skills (1)
- Mountain (1)
- Mouse (1)
- Mouse model (1)
- Mouse models (1)
- Moviprep (1)
- Multi-modal feedback (1)
- Multidisciplinary management (1)
- Multidrug resistance (1)
- Multiple sclerosis (1)
- Multivariate analysis (1)
- Muscle tissue (1)
- Musician-specific seating position (1)
- Myalgia (1)
- Myelofibrosis (1)
- Myocardial infarction (1)
- Myocardial revascularization (1)
- N-Acetylaspartate (1)
- N-acetylcysteine (1)
- N-methyl-D-aspartate receptor (1)
- NAFLD (1)
- NASH (1)
- NDNF interneurons (1)
- NDUFA6 (1)
- NK cells (1)
- NKG2A blocking (1)
- NKG2D (1)
- NK cells (1)
- NOD2 (1)
- NSTEMI (1)
- Nanoparticles (1)
- Natriuretic peptide (1)
- Necrosis (1)
- Necrotizing enterocolitis (1)
- Needs assessment [MeSH] (1)
- Negative staining (1)
- Neoadjuvant therapy (1)
- Neonatal (1)
- Neonatal intensive care unit (1)
- Neonatal morbidity (1)
- Nephrons (1)
- Nerve regeneration (1)
- Nerves (1)
- Neural circuits (1)
- Neurobiology of disease and regeneration (1)
- Neurodevelopment (1)
- Neuroendocrine cancer (1)
- Neuroimaging (1)
- Neutropenia (1)
- Next generation sequencing (1)
- Nfe2l2 (1)
- Niche differentiation (1)
- Nimotuzumab (1)
- Nitric oxide (1)
- Non-interventional study (1)
- Non-responder (1)
- Non-small-cell lung cancer (1)
- Non-trauma (1)
- Noncoding RNA (1)
- Normal distribution (1)
- Nox1 (1)
- Nox4 (1)
- NoxO1 (1)
- Nucleus pulposus cells (1)
- Nutrition (1)
- Nymphs (1)
- OCT (1)
- Observational studies (1)
- Obstetrics and gynecology (1)
- Ocular findings (1)
- Oesophageal cancer (1)
- Okinawa (1)
- Okinawa diet (1)
- Older adults (1)
- Oncologic surgery (1)
- Open abdomen (1)
- Optic nerve atrophy (1)
- Optogenetics (1)
- Oral and maxillofacial trauma (1)
- Oral anticoagulation (1)
- Oral surgery (1)
- Ordinary least squares (OLS) (1)
- Organ dysfunction (1)
- Organ dysfunctions (1)
- Organ support (1)
- Organs at Risk (1)
- Oroantral (1)
- Osimertinib (1)
- Osteogenic differentiation (1)
- Outcome assessment (1)
- Outcome assessment [MeSH] (1)
- OxyELITE Pro (1)
- P-gp (1)
- P1NP (1)
- P2X7 receptor (1)
- PAH (1)
- PAI-1 (1)
- PBX1 (1)
- PC12 cells (1)
- PCV (1)
- PD-L1 (1)
- PEGylated PLGA (PLGA-PEG) (1)
- PFL (1)
- PI3K (1)
- PKA (1)
- PTCH (1)
- PTDM (1)
- PTK2B (1)
- Pacemaker (1)
- Pain (1)
- Pancreatitis (1)
- Parkin (1)
- Parkinson disease (1)
- Pathological complete response (1)
- Pathology (1)
- Patient Blood Management (1)
- Patient Outcome Assessment (1)
- Patient satisfaction (1)
- Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (1)
- Pediatrics [MeSH] (1)
- Peer Teaching (1)
- Peer teaching (1)
- Periodontal diseases (1)
- Peritonitis (1)
- Personality (1)
- Personalized medicine (1)
- Pessar (1)
- Pharmacy setting (1)
- Pharyngeal reflex (1)
- Phospho-soda (1)
- Phospholipids (1)
- Phosphorylation (1)
- Phylogenetic analysis (1)
- Physical environment (1)
- Physicians (1)
- Physiology (1)
- PillCamColon2 (1)
- Polyps (1)
- Portal hypertension (1)
- Position paper (1)
- Post-transplant (1)
- Postoperative infections (1)
- Posttranslational modification (1)
- Postural control (1)
- Poverty (1)
- Practice (1)
- Preclinical (1)
- Pregnancy (1)
- Preterm birth (1)
- Primary health care (1)
- Progesteron (1)
- Progesterone (1)
- Prognostic markers (1)
- Programming languages (1)
- Progranulin (1)
- Proliferation (1)
- Prostate Cancer (1)
- Prostate cancer cell lines (1)
- Prosthetic rehabilitation (1)
- Protein domains (1)
- Protein translation (1)
- Proteins (1)
- Prothrombin complex concentrate (1)
- Prüfungsfragen (1)
- Psychiatric disorders (1)
- Psychology (1)
- Public and occupational health (1)
- Pulmonary artery pressure (1)
- Pulmonary embolism (1)
- Pyruvate (1)
- Qualitative research [MeSH] (1)
- Quality of health care [MeSH] (1)
- Quality of life (1)
- Quantitative MRI (1)
- Quantitative trait loci (1)
- Questionnaires (1)
- Quinolinate phosphoribosyltransferase (1)
- Quinolinic acid (1)
- RNA therapy (1)
- RNA viruses (1)
- ROS (1)
- Rab7 (1)
- Radical nephrectomy (1)
- Rainfall (1)
- Randomized (1)
- RapL (1)
- Rapamycin (1)
- Rare diseases (1)
- Re-exploration (1)
- Rearing temperature (1)
- Red blood cell transfusion (1)
- Redox modification (1)
- Regeneration (1)
- Regression analysis (1)
- Regulatory networks (1)
- Reintervention (1)
- Remote monitoring (1)
- Renal cancer (1)
- Renal system (1)
- Research Article (1)
- Research architecture (1)
- Resource competition (1)
- Respiratory tract diseases (1)
- Response criteria (1)
- Resuscitation (1)
- Retinal degeneration (1)
- Rheumatoid arthritis (1)
- Rivaroxaban (1)
- Rural area (1)
- Ruxolitinib (1)
- S1P (1)
- SAVI (1)
- SCMR (1)
- SDH (1)
- SKAP1 (1)
- SMAD signaling (1)
- SOFA (1)
- STING (1)
- Safety equipment (1)
- Safety learning (1)
- Sarcoidosis (1)
- Scientific publishing (1)
- Secretion (1)
- Senescence (1)
- Sensitivity (1)
- Sensory Neuroscience (1)
- Sensory processing (1)
- Septic shock (1)
- Sequence alignment (1)
- Serum (1)
- Severe blood loss (1)
- Severity of illness index (1)
- Sex differences (1)
- Shannon index (1)
- Sholl analysis (1)
- Simulated patients (1)
- Single-cell RNA-seq (1)
- Smac mimetic (1)
- Small molecules (1)
- Small-cell lung cancer (1)
- Smart nebulizer (1)
- Smoking habits (1)
- Social communication (1)
- Social research (1)
- Social sciences (1)
- Solidworks 2015 (1)
- Sphingolipids (1)
- Spine Register (1)
- Spirochetes (1)
- Sports (1)
- Sports and exercise medicine (1)
- Spot sign (1)
- Standards of care (1)
- Starvation (1)
- Statistical data (1)
- Statistical methods (1)
- Status epilepticus (1)
- Stenotrophomonas maltophilia (1)
- Stereotactic radiosurgery (1)
- Stoma (1)
- Streptococcus pneumoniae (1)
- Stringed bow player (1)
- Structural MRI (1)
- Structural genomics (1)
- Study protocol (1)
- Suicide (1)
- Sulfasalazine (1)
- Sumatra (1)
- Supraspinatus tendon (1)
- Surgical ICU (1)
- Surgical site occurrence (1)
- Survival analysis (1)
- Survival data (1)
- Sweat osmolality (1)
- Sweat secretion rate (1)
- Syncope (1)
- Synthetic (1)
- T cell (1)
- T cells (1)
- T helper 17 cells (1)
- T-DM1 (1)
- T-cell targeting (1)
- T-cells (1)
- T1 mapping (1)
- TALE-homdomain protein (1)
- TAVR (1)
- TBSS (1)
- TC stenosis (1)
- TF-complexes (1)
- TMS-EEG (1)
- TNF inhibitors (1)
- TNF-α (1)
- TOR inhibitor (1)
- TP53 mutation status (1)
- Targeted therapy (1)
- Taxonomy (1)
- Technique (1)
- Telemedicine (1)
- Temporal lobe epilepsy (1)
- Term birth (1)
- Testosterone (1)
- Tet-inducible system (1)
- Thailand (1)
- Thermoregulation (1)
- Three-dimensional back scan (1)
- Thrombosis (1)
- Thyroid (1)
- Tick-Borne diseases (1)
- Tick-borne encephalitis (1)
- Timing (1)
- Tinnitus (1)
- Tomography (1)
- Tooth transplantation (1)
- Torque (1)
- Toxicity (1)
- Training (1)
- Tranexamic acid (1)
- Transcription (1)
- Transcription Factors (1)
- Transcription factors (1)
- Transferases (1)
- Transfusion (1)
- Transgenic SK-2 mice (1)
- Trauma surgery (1)
- Traumatic brain injury (1)
- Traumatic injury (1)
- Treatment (1)
- Trichuris suis ova (1)
- Triple negative (1)
- Triple therapy (1)
- Triple-negative breast cancer (1)
- Troponin (1)
- Tubers (1)
- Tumor infiltrating lymphocytes (1)
- Tumour biomarkers (1)
- Type 2 diabetes (1)
- UDP-glucose ceramide glycosyltransferase (1)
- UGCG (1)
- ULBP4 (1)
- UWB diagnostics (1)
- Ubiquitin (1)
- Ubiquitination (1)
- Ultra microscopy (1)
- Ultrasonic nebulizer (1)
- Ultrasound imaging (1)
- Upper body posture (1)
- Usutu virus (1)
- V4 (1)
- VEGF (1)
- VIP1 (1)
- Vaccination breakthrough (1)
- Vaccine (1)
- Vascular emergencies (1)
- Vector mosquito (1)
- Viral core (1)
- Viral replication (1)
- Vision (1)
- Visual acuity (1)
- Vitamin (1)
- Volumetric analysis (1)
- Vorklinik (1)
- Warburg effect (1)
- Water chemistry (1)
- Weight loss (1)
- West Nile fever (1)
- West Nile neuroinvasive disease (1)
- West Nile virus (1)
- Work shadowing (1)
- Working memory (1)
- X-ray crystallography (1)
- XL probe (1)
- Yarrowia lipolytica (1)
- Zervixverkürzung (1)
- Zika (1)
- Zika vaccine (1)
- Zika virus (1)
- Zirconia (1)
- Zoopotentation (1)
- Zooprophylaxis (1)
- abemaciclib (1)
- abnormal tumor vasculature (1)
- accident (1)
- acetaminophen (1)
- acetyl-CoA (1)
- activation receptors (1)
- active/deactive transition (1)
- actography (1)
- acute cholecystitis (1)
- acute coronary syndrome (1)
- acute exacerbations of COPD (1)
- acute inflammation (1)
- acute myeloid leukemia (1)
- adaptation (1)
- adenosine receptors (1)
- adherence (1)
- adhesion (1)
- adipose-derived mesenchymal stem cells (1)
- adoptive cell therapy (1)
- adoptive immunotherapy (1)
- advanced breast cancer (1)
- adverse reaction (1)
- aerosol (1)
- aggression (1)
- airway remodeling (1)
- aliphatic halogenated hydrocarbons (1)
- alirocumab (1)
- allergen immunotherapy (1)
- allergic rhinitis (1)
- allogeneic stem cell transplantation (1)
- alpinia zerumbet (1)
- anaesthesia in orthopaedics (1)
- anaesthetics (1)
- anastomotic leakage (1)
- anatomy (1)
- anatomy and histology (1)
- anti-GD2 immunotherapy (1)
- anti-inflammatory (1)
- antibiotic (1)
- antibiotic therapy (1)
- antibodies (1)
- anticonvulsants (1)
- antihormone therapy (1)
- antimicrobial activity (1)
- antioxidant (1)
- antioxidant activity (1)
- antisense oligonucleotides (1)
- aortic stenosis (1)
- apoptosis (1)
- apps (1)
- aptamer (1)
- aquaporin 1 (1)
- arachidonate 15-lipoxygenase (1)
- arachidonic acid (1)
- ascites (1)
- asthma (1)
- atrial fibrillation (1)
- atrial septostomy (1)
- atrophy (1)
- autoimmunity (1)
- autologous stem cell transplantation (1)
- avelumab (1)
- back scan (1)
- bacterium (1)
- balanced state (1)
- basal cell carcinoma (1)
- basic leucine zipper transcription factor ATF-like (1)
- beta blockade (1)
- betamethasone dipropionate (1)
- bevacizumab (1)
- bibliometric analysis (1)
- bibliometry (1)
- bio imaging (1)
- bioactive phytochemicals (1)
- bioluminescence (1)
- biomarker (1)
- biopsy (1)
- bipolar disorders (1)
- birch pollen allergoid (1)
- blood (1)
- blood donor (1)
- blow flies (1)
- blow fly (1)
- body posture (1)
- borrelia (1)
- brachytherapy (1)
- bronchodilator (1)
- buccal mucosa (1)
- cAMP (1)
- cFLIP (1)
- calcification score (1)
- calcipotriol (1)
- calcium-independent phospholipase A2β (1)
- cancer stem cells (1)
- carbon tetrachloride (1)
- cardiovascular diseases (1)
- cardiovascular precision medicine (1)
- caspase-2 (1)
- ceRNA (1)
- celery (1)
- cell biology (1)
- cell cycle (1)
- cell migration (1)
- cellular signalling (1)
- centenarians (1)
- cerclage (1)
- cerebrospinal fluid (1)
- cervical cancer (1)
- cervical shortening (1)
- cervical spine (1)
- cervico-thoracic junction (1)
- ch14.18/CHO (1)
- chamomile (1)
- checkpoint inhibition (1)
- chemokine (1)
- chemotaxis (1)
- chemotherapeutic drug resistance (1)
- child abuse and neglect (1)
- child maltreatment (1)
- children (1)
- cholangiocarcinoma (1)
- cholesterol (1)
- chromosomal integration (1)
- cilia (1)
- circadian rhythms (1)
- circadian variation (1)
- cisplatin resistance (1)
- clinical management (1)
- clinical practice (1)
- clinical trial (1)
- cognition (1)
- cognitive states (1)
- cohort study (1)
- colitis (1)
- collagen (1)
- collagen-based biomaterial (1)
- collective dynamics (1)
- colon (1)
- colon carcinoma cells (1)
- column chromatography (1)
- combination (1)
- combination therapy (1)
- combined immunodeficiency (1)
- complement dependent cytotoxicity (1)
- complementary information (1)
- complex I (1)
- complexome profiling (1)
- complications (1)
- computational virology (1)
- computer-assisted drug therapy (1)
- congenic mice (1)
- contact lens solution (1)
- continuous glucose monitoring (1)
- controlled nuclear import (1)
- coronary (1)
- coronary disease (1)
- correction of incidence rate (1)
- correction of mortality rate (1)
- corrosion (1)
- criticality (1)
- cryoballoon (1)
- cumulative dose (1)
- curriculum (1)
- cytarabine dose (1)
- cytochrome P450 2E1 (1)
- cytokine release syndrome (1)
- cytokine-induced killer cells (1)
- cytotoxic T cells (1)
- dabrafenib (1)
- damage associated molecular pattern (1)
- decision aids (1)
- delayed cholecystectomy (1)
- delta-9-tetrahydrocannabinol (1)
- dendritic cells (1)
- dendritic inhibition (1)
- dental abutment (1)
- dental implants (1)
- dermatology (1)
- dexamethasone (1)
- diabetes (1)
- diabetic macular edema (1)
- diagnostics (1)
- dietary supplements (1)
- differentiated thyroid carcinoma (1)
- differentiation (1)
- diffuse low-grade glioma (1)
- digital age determination (1)
- dihydroceramides (1)
- diplopia (1)
- direct-acting antivirals (1)
- disease progression (1)
- disintegration (1)
- dose response curve (1)
- doxorubicin (1)
- doxycycline (1)
- drug interaction (1)
- drug release (1)
- drug-coated balloon (1)
- drug-eluting balloon (1)
- dynamic stimuli (1)
- eNPP2 (1)
- early cholecystectomy (1)
- educational cases (1)
- educational measurement (1)
- efficacy (1)
- elderly (1)
- embodiment (1)
- emulsion diffusion (1)
- encoding (1)
- endogenous clock (1)
- endoplasmic reticulum (1)
- endothelial activation (1)
- endothelial barrier (1)
- endothelial cell (1)
- endothelial nitric-oxide synthase (1)
- epidemics (1)
- epidemiology (1)
- epileptic encephalopathies (1)
- event-based (1)
- excitability (1)
- exercise (1)
- exosomes (1)
- exponential model (1)
- extracting solvents (1)
- fMRI (1)
- face (1)
- facial EMG (1)
- facial emotion recognition (1)
- facial expressions of emotion (1)
- facial muscle activity (1)
- factor H (1)
- falls (1)
- false memory (1)
- fear learning (1)
- female subjects (1)
- femoropopliteal segment (1)
- fibrinolysis (1)
- fibrosis (1)
- flow cytometry (1)
- fluocinolone acetonide (1)
- focal adhesion (1)
- forensics (1)
- functional connectivity (1)
- functional genomics (1)
- functional magnetic resonance imaging (fMRI) (1)
- fungus (1)
- galactomannan (1)
- gallstone disease (1)
- gastric cancer (1)
- gastro-oesophageal junction cancer (1)
- gene delivery (1)
- gene therapy (1)
- gene vectors (1)
- general anaesthesia (1)
- general practice (1)
- genetic markers (1)
- geriatric medicine (1)
- germinal center (1)
- glioma (1)
- glioma-associated oncogene homolog (1)
- gliomas (1)
- global mapping (1)
- glucocorticoid (1)
- glucose metabolism (1)
- glycolysis (1)
- graft perfusion (1)
- graft rejection (1)
- graft-versus-host disease (1)
- graft-versus-tumor effect (1)
- granulocytemacrophage colony-stimulating factor (1)
- granulomas (1)
- granulomatous inflammation (1)
- green tea extract (1)
- hanging donors (1)
- head and neck squamous cell carcinoma (1)
- head-and-neck cancer (1)
- headache (1)
- health (1)
- health care personnel (1)
- health information exchange (1)
- health services accessibility (1)
- health-related quality of life (1)
- heart failure (1)
- hedgehog signaling pathway (1)
- helminths (1)
- hematopoietic stem cells (1)
- hepatitis B virus (1)
- hepatitis C virus (HCV) (1)
- hepatitis E virus (1)
- hepatocyte transplantation (1)
- hereditary angioedema (1)
- hierarchy (1)
- hippocampal neuronal cell line (1)
- histone acetylation (1)
- histone deacetylase (1)
- histone deacetylase 5 (1)
- host-targeting antivirals (1)
- human biology and medicine (1)
- human papilloma virus (1)
- human renal proximal tubular epithelial cells (1)
- humanized mouse (1)
- humans (1)
- humoral factors (1)
- hybrid (1)
- hydrocephalus (1)
- hydroxyapatite crystals (1)
- hyperbaric oxygen treatment (1)
- hyperlipidemia (1)
- hypothalamus (1)
- hypoxia-induced cell death (1)
- imitation (1)
- immune (1)
- immune reconstitution (1)
- immunohistochemistry (1)
- in-cabin exposure (1)
- inducible gene expression (1)
- infectivity (1)
- inflammasome (1)
- influenza (1)
- influenza vaccine (1)
- information decomposition (1)
- inhaler (1)
- innate lymphoid cells (1)
- insulin resistance (1)
- integration (1)
- integrin (1)
- integrins (1)
- interferon (1)
- interferon gamma (1)
- interleukin-1 (1)
- interleukin-18 (1)
- interleukin-1β (1)
- interleukin-23 receptor (1)
- interneurons (1)
- interstitial brachytherapy (1)
- intervertebral disc degeneration (1)
- intestinal graft-versushost disease (1)
- intracellular trafficking (1)
- intraperitoneal therapy (1)
- intraventricular chemotherapy (1)
- invasion (1)
- ionomycin (1)
- irradiation (1)
- ischemic type biliary lesions (1)
- isocaloric ketogenic diet (1)
- isovaleric acidaemia (1)
- kavalactones (1)
- keratinocytes (1)
- kinase inhibitor (1)
- knockout mice (1)
- knowledge discovery (1)
- laceration (1)
- lapatinib (1)
- late lumen loss (1)
- layer 1 (1)
- leptomeningeal metastases (1)
- levetiracetam (1)
- lipoxygenase (1)
- liver cirrhosis (1)
- liver fibrosis (1)
- liver transplantation (1)
- long-acting muscarinic antagonist (1)
- long-term follow-up (1)
- long-term infusion (1)
- longevity (1)
- lung cancer (1)
- lung remodeling (1)
- lung transplantation (1)
- lymphocyte (1)
- lymphoma (1)
- mTOR (1)
- mTOR inhibitor (1)
- mTORC1 (1)
- machine-learning (1)
- macula (1)
- magnetoencephalography (1)
- maintenance (1)
- malignancy (1)
- marginal bone loss (1)
- markovianity (1)
- massively parallel multigrid solvers (1)
- maternal care (1)
- mathematical modeling (1)
- measure development/validation (1)
- mechanobactericidal surfaces (1)
- medical illustration (1)
- medical school (1)
- medication reconciliation (1)
- memebrane (1)
- mentoring (1)
- metabolic cancer therapy (1)
- metamorphosis (1)
- metastatic (1)
- methotrexate (1)
- methyltransferases (1)
- miR-122 (1)
- miR-21 (1)
- microdosing (1)
- microsaccades (1)
- microsatellite instability (1)
- microwave breast imaging (1)
- migrants (1)
- migration (1)
- mitochondrial disease (1)
- mobile air quality study (1)
- moisturing cream (1)
- molecular identification (1)
- molecular mechanisms (1)
- momilactone A (1)
- momilactone B (1)
- monkey (1)
- mouse (1)
- multidrug resistance (1)
- multimorbidity (1)
- multinucleated giant cells (1)
- multiple chronic conditions (1)
- multiple myeloma (1)
- multiple sclerosis (1)
- multisite cooperation (1)
- myocyte enhancer factor 2 (1)
- nanostructures (1)
- natural killer T cells (1)
- natural killer cell (1)
- neocortical circuits (1)
- neoepitopes (1)
- neonatal intensive care unit (1)
- neonate (1)
- neural network (1)
- neural oscillations (1)
- neuraminidase inhibitor (1)
- neuro-ophthalmological examination (1)
- neuroblastoma (1)
- neurocognition (1)
- neurocritical care (1)
- neurogenesis (1)
- neurological emergencies (1)
- neuromodulation (1)
- neurophysiology (1)
- neuropilin-1 (1)
- nitric oxide (1)
- nitro-fatty acids (1)
- non-ST-segment elevation acute coronary syndrome (1)
- nonalcoholic fatty liver disease (1)
- nonalcoholic steatohepatitis (1)
- nonviral gene delivery (1)
- novel psychoactive substance (1)
- nursery school students (1)
- nursery schools (1)
- nursery students (1)
- nurses (1)
- obese (1)
- object tracking (1)
- omega-3 fatty acids (1)
- oncogene (1)
- one health (1)
- open-source (1)
- oral kallikrein inhibitor (1)
- orthopic liver transplantation (1)
- oscillations (1)
- oseltamivir (1)
- ostium (1)
- outcome (1)
- outcomes (1)
- ovarian cancer (1)
- oxygen (1)
- p21-activated kinase 2 (1)
- p38 (1)
- p97 (1)
- pCREB (1)
- palbociclib (1)
- palmitoylation (1)
- papilloma (1)
- parameter estimation (1)
- parsley (1)
- particle size distribution (1)
- particulate matter (1)
- patency (1)
- patient study (1)
- patients (1)
- pentose phosphate pathway (1)
- pericytes (1)
- peripheral artery disease (1)
- peripheral vascular diseases (1)
- peritoneal carcinomatosis (1)
- persistent atrial fibrillation (1)
- persisting pain (1)
- personalized oncology (1)
- pertuzumab (1)
- pessary (1)
- pharmacology (1)
- phase III (1)
- phase-1 (1)
- phenolics (1)
- phenylephrine (1)
- phosphate (1)
- photoaging (1)
- physical activity (1)
- physical activity promotion (1)
- physical activity recommendations (1)
- pictilisib (1)
- pig (1)
- pivalate (1)
- pivoloyl (1)
- plasminogen (1)
- platform-switched (1)
- polarization (1)
- poly(I:C) (1)
- poly(lactic-co-glycolic acid) (PLGA) (1)
- polydipsia (1)
- polylactic acid (PLA) (1)
- polymerase chain reaction (1)
- polypharmacy (1)
- polyphenols (1)
- polytrauma (1)
- polyuria (1)
- popliteal artery (1)
- porcine (1)
- post-transplantation lymphoproliferative disease (1)
- posttranslational modification (1)
- pre-emptive allogeneic hematopoietic stem cell transplantation (1)
- preclinical semesters (1)
- preconditioning (1)
- pressure (1)
- pressurized intraperitoneal aerosol chemotherapy (PIPAC) (1)
- preterm (1)
- preterm birth (1)
- pretreatment (1)
- prevalence of hysterectomy (1)
- prevent smoking (1)
- primary cilium (1)
- primary healthcare (1)
- primary mouse proximal tubular cells (1)
- progesterone (1)
- programmed cell death ligand 1 (1)
- programmed cell death protein 1 (1)
- proliferation (1)
- prophylaxis (1)
- propofol anesthesia (1)
- prospective memory (1)
- prostaglandin E2 (1)
- prostate cancer (1)
- protein kinase D (1)
- protein kinases (1)
- proteomics (1)
- pruritus (1)
- psoriatic arthritis (1)
- psychological questionnaires (1)
- psychometric properties (1)
- publication (1)
- pulmonary arterial hypertension (1)
- pulmonary inflammation (1)
- pulmonary vein isolation (1)
- qPCR (1)
- qRT-PCR (1)
- qualitative research (1)
- quality control (1)
- radical scavenging chemicals (1)
- radiofrequency (1)
- radiotherapy (1)
- radiotherapy resistance (1)
- rare diseases (1)
- rat (1)
- real-world evidence (1)
- realistic geometries (1)
- redox signalling (1)
- redox-linked proton translocation (1)
- redundancy (1)
- redundant information (1)
- reference values (1)
- regulatory T cell (1)
- relapsing–remitting (1)
- reliability (1)
- remote ischemic preconditioning (1)
- renal cell cancer (1)
- renal cell carcinoma (1)
- renal failure (1)
- renal ischemia reperfusion injury (1)
- research consortium (1)
- resilience (1)
- respiratory complex I (1)
- restenosis (1)
- restrictive atrial communication (1)
- retina (1)
- retinoic acid-related orphan receptor gamma t (1)
- rhodocetin-αβ (1)
- rhythm (1)
- ribociclib (1)
- rice husk (1)
- risk assessment (1)
- rural health program (1)
- saliva (1)
- school-based prevention (1)
- scientometrics (1)
- scientometry (1)
- screening routine (1)
- secretion (1)
- selection (1)
- selective attention (1)
- selective mutism, (1)
- semen (1)
- sensitization (1)
- sensory neurons (1)
- sequential ALK-inhibitor therapy (1)
- shedding (1)
- shell ginger (1)
- shortage of family doctors (1)
- siRNA (1)
- signaling (1)
- silence interfering RNA (1)
- sirtuin1 (1)
- sirtuins (1)
- skeletal muscle (1)
- skin (1)
- smoking (1)
- smoking cessation (1)
- solvent displacement (1)
- somatostatin interneurons (1)
- sonidegib (1)
- spatial (1)
- sphinganine 1-phosphate (1)
- sphingosine kinase 1 (1)
- spinster homology protein 2 (Spns2) (1)
- spirochetes (1)
- squamous cell carcinoma (1)
- standard value (1)
- stem cell niche (1)
- stem cells (1)
- stenosis (1)
- stenosis quantification (1)
- sterol regulatory element binding protein-2 (1)
- stroke (1)
- structural biology and molecular biophysics (1)
- subcutaneous immunotherapy (1)
- sublingual immunotherapy (1)
- subventricular zone (1)
- superficial femoral artery (1)
- syncope (1)
- synergy (1)
- tear (1)
- temozolomide (1)
- temperature (1)
- temsirolimus (1)
- testicular cancer (1)
- tetracycline (1)
- tetrahydrobiopterin (1)
- thymus (1)
- titanium (1)
- titanium particles (1)
- tobacco (1)
- tobacco cessation (1)
- tomography (1)
- top-down processing (1)
- topical agent (1)
- total events (1)
- total flavonoids (1)
- total phenols (1)
- toxicity (1)
- tracking (1)
- traffic emissions (1)
- transcatheter aortic valve replacement (1)
- transcranial magnetic stimulation (1)
- transcriptome analysis (1)
- transfemoral (1)
- transgelin (1)
- transient elastography (1)
- transiente Elastographie (1)
- transketolase-like protein 1 (1)
- translational cancer research (1)
- transposition (1)
- trastuzumab (1)
- trauma (1)
- trehalose (1)
- tubular regeneration (1)
- tumor metabolism (1)
- tumor-infiltrating lymphocytes (1)
- type B (1)
- ubiquitin (1)
- unique information (1)
- upper gastrointestinal cancer (1)
- vaccination rates (1)
- vaccine (1)
- vaccine acceptance (1)
- vaccine trial (1)
- validity (1)
- vascular calcification (1)
- vascular endothelial growth factor receptor 2 (1)
- vascular smooth muscle cells (1)
- vasculogenic mimicry (1)
- vasoconstriction (1)
- vasodilation (1)
- vasopressin (1)
- ventilation modes (1)
- ventral striatum (1)
- ventriculoperitoneal shunt (1)
- vesicular glutamate transporter 2 (1)
- vessel-associated mural cells (1)
- videos (1)
- viral dynamics (1)
- virus (1)
- virus-like particles (1)
- vision (1)
- vismodegib (1)
- vismodegib (GDC-0449) (1)
- visual cortex (1)
- visuo-spatial attention (1)
- vitamin D (1)
- vitamin D receptor (1)
- wear (1)
- white-matter (1)
- wild animals (1)
- willingness to participate (1)
- within-host viral modelling (1)
- working memory (1)
- wound healing (1)
- yield optimization (1)
- ß-D-glucan (1)
- α-mannosidosis (1)
Institute
- Medizin (472)
- Präsidium (14)
- Sonderforschungsbereiche / Forschungskollegs (14)
- Exzellenzcluster Makromolekulare Komplexe (9)
- Biowissenschaften (8)
- Sportwissenschaften (8)
- Exzellenzcluster Herz-Lungen-System (7)
- Georg-Speyer-Haus (6)
- Pharmazie (6)
- Psychologie (6)
Background: There currently are no internationally recognised treatment guidelines for patients with advanced gastric cancer/gastro-oesophageal junction cancer (GC/GEJC) in whom two prior lines of therapy have failed. The randomised, phase III JAVELIN Gastric 300 trial compared avelumab versus physician’s choice of chemotherapy as third-line therapy in patients with advanced GC/GEJC.
Patients and methods: Patients with unresectable, recurrent, locally advanced, or metastatic GC/GEJC were recruited at 147 sites globally. All patients were randomised to receive either avelumab 10 mg/kg by intravenous infusion every 2 weeks or physician’s choice of chemotherapy (paclitaxel 80 mg/m2 on days 1, 8, and 15 or irinotecan 150 mg/m2 on days 1 and 15, each of a 4-week treatment cycle); patients ineligible for chemotherapy received best supportive care. The primary end point was overall survival (OS). Secondary end points included progression-free survival (PFS), objective response rate (ORR), and safety.
Results: A total of 371 patients were randomised. The trial did not meet its primary end point of improving OS {median, 4.6 versus 5.0 months; hazard ratio (HR)=1.1 [95% confidence interval (CI) 0.9–1.4]; P= 0.81} or the secondary end points of PFS [median, 1.4 versus 2.7 months; HR=1.73 (95% CI 1.4–2.2); P> 0.99] or ORR (2.2% versus 4.3%) in the avelumab versus chemotherapy arms, respectively. Treatment-related adverse events (TRAEs) of any grade occurred in 90 patients (48.9%) and 131 patients (74.0%) in the avelumab and chemotherapy arms, respectively. Grade ≥3 TRAEs occurred in 17 patients (9.2%) in the avelumab arm and in 56 patients (31.6%) in the chemotherapy arm.
Conclusions: Treatment of patients with GC/GEJC with single-agent avelumab in the third-line setting did not result in an improvement in OS or PFS compared with chemotherapy. Avelumab showed a more manageable safety profile than chemotherapy.
Trial registration: ClinicalTrials.gov: NCT02625623.
Background: We analyzed whether co-occurring mutations influence the outcome of systemic therapy in ALK-rearranged non-small-cell lung cancer (NSCLC).
Patients and methods: ALK-rearranged stage IIIB/IV NSCLC patients were analyzed with next-generation sequencing and fluorescence in situ hybridization analyses on a centralized diagnostic platform. Median progression-free survival (PFS) and overall survival (OS) were determined in the total cohort and in treatment-related sub-cohorts. Cox regression analyses were carried out to exclude confounders.
Results: Among 216 patients with ALK-rearranged NSCLC, the frequency of pathogenic TP53 mutations was 23.8%, while other co-occurring mutations were rare events. In ALK/TP53 co-mutated patients, median PFS and OS were significantly lower compared with TP53 wildtype patients [PFS 3.9 months (95% CI: 2.4–5.6) versus 10.3 months (95% CI: 8.6–12.0), P < 0.001; OS 15.0 months (95% CI: 5.0–24.9) versus 50.0 months (95% CI: 22.9–77.1), P = 0.002]. This difference was confirmed in all treatment-related subgroups including chemotherapy only [PFS first-line chemotherapy 2.6 months (95% CI: 1.3–4.1) versus 6.2 months (95% CI: 1.8–10.5), P = 0.021; OS 2.0 months (95% CI: 0.0–4.6) versus 9.0 months (95% CI: 6.1–11.9), P = 0.035], crizotinib plus chemotherapy [PFS crizotinib 5.0 months (95% CI: 2.9–7.2) versus 14.0 months (95% CI: 8.0–20.1), P < 0.001; OS 17.0 months (95% CI: 6.7–27.3) versus not reached, P = 0.049] and crizotinib followed by next-generation ALK-inhibitor [PFS next-generation inhibitor 5.4 months (95% CI: 0.1–10.7) versus 9.9 months (95% CI: 6.4–13.5), P = 0.039; OS 7.0 months versus 50.0 months (95% CI: not reached), P = 0.001).
Conclusions: In ALK-rearranged NSCLC co-occurring TP53 mutations predict an unfavorable outcome of systemic therapy. Our observations encourage future research to understand the underlying molecular mechanisms and to improve treatment outcome of the ALK/TP53 co-mutated subgroup.
BACKGROUND: Adjuvant chemotherapy (ACT) for breast cancer improves relapse-free survival (BCRFS) and overall survival. Differences in terms of efficacy and toxicity could partly be explained by the significant interpatient variability in pharmacokinetics which cannot be captured by dosing according to body surface area. Consequently, tailored dosing was prospectively evaluated in the PANTHER trial.
PATIENTS AND METHODS: PANTHER is a multicenter, open-label, randomized phase III trial which compared tailored, dose-dense (DD) epirubicin/cyclophosphamide (E/C) and tailored docetaxel (D) (tDD) with standard interval 5-fluorouracil/E/C and D. The primary end point was BCRFS and the primary efficacy analysis has been previously published. In this secondary analysis, we aimed to retrospectively explore the concept of dose tailoring. Our two hypotheses were that BCRFS would not vary depending on the cumulative administered epirubicin dose; and that dose tailoring would lead to appropriate dosing and improved outcomes for obese patients, who are known to have worse prognosis and increased toxicity after DD ACT.
RESULTS: Patients treated with tDD had similar BCRFS regardless of the cumulative epirubicin dose (P = 0.495), while obese patients in this group [body mass index (BMI) ≥30] had improved BCRFS compared with nonobese ones (BMI <30) [hazard ratio (HR) = 0.51, 95% confidence interval (CI) 0.30-0.89, P = 0.02]. Moreover, tDD was associated with improved BCRFS compared with standard treatment only in obese patients (HR = 0.49, 95% CI 0.26-0.90, P = 0.022) but not in nonobese ones (HR = 0.79, 95% CI 0.60-1.04, P = 0.089). The differences were not formally statistically significant (P for interaction 0.175). There were no differences in terms of toxicity across the epirubicin dose levels or the BMI groups.
CONCLUSIONS: Dose tailoring is a feasible strategy that can potentially improve outcomes in obese patients without increasing toxicity and should be pursued in further clinical studies.
Background: Understanding the location and cell-type specific binding of Transcription Factors (TFs) is important in the study of gene regulation. Computational prediction of TF binding sites is challenging, because TFs often bind only to short DNA motifs and cell-type specific co-factors may work together with the same TF to determine binding. Here, we consider the problem of learning a general model for the prediction of TF binding using DNase1-seq data and TF motif description in form of position specific energy matrices (PSEMs).
Methods: We use TF ChIP-seq data as a gold-standard for model training and evaluation. Our contribution is a novel ensemble learning approach using random forest classifiers. In the context of the ENCODE-DREAM in vivo TF binding site prediction challenge we consider different learning setups.
Results: Our results indicate that the ensemble learning approach is able to better generalize across tissues and cell-types compared to individual tissue-specific classifiers or a classifier applied to the data aggregated across tissues. Furthermore, we show that incorporating DNase1-seq peaks is essential to reduce the false positive rate of TF binding predictions compared to considering the raw DNase1 signal.
Conclusions: Analysis of important features reveals that the models preferentially select motifs of other TFs that are close interaction partners in existing protein protein-interaction networks. Code generated in the scope of this project is available on GitHub: https://github.com/SchulzLab/TFAnalysis (DOI: 10.5281/zenodo.1409697)
A recent randomized study of whipworm Trichuris suis ova (TSO) in ileal Crohn’s disease failed to demonstrate a clinical benefit compared to placebo after 12 weeks. Nonetheless, it has recently been shown that the spontaneous small intestinal inflammatory changes in Nod2-/- (Nucleotide-binding oligomerization domain 2) mice could be substantially ameliorated when these mice were colonized by Trichuris muris. Those and complementary epidemiologic findings in humans lead to the hypothesis that helminths may be advantageous only in patients carrying defective NOD2 variants. Thus, 207 participants of the TSO trial were retrospectively genotyped for six functional NOD2 genetic variants to evaluate whether the treatment outcome differed in patients carrying NOD2 variants. We observed no significant association of the NOD2 variants or their haplotypes with clinical outcome after TSO treatment.
Background: Real‐world evidence is sparse on the benefits of allergen immunotherapy [AIT; subcutaneous/sublingual immunotherapy (SCIT/SLIT)], the only disease‐modifying intervention for allergic rhinitis (AR) with long‐term efficacy. This real‐life study evaluated the effect of six AITs (native pollen SLIT/SCIT, four allergoid SCITs) vs symptomatic medication use, on AR symptoms and asthma symptoms/onset, in patients with birch pollen‐associated AR and/or asthma.
Methods: In this retrospective cohort analysis of a German longitudinal prescription database, AIT patients received ≥2 successive seasonal treatment cycles; non‐AIT patients had ≥3 AR prescriptions in three seasons or previous month. Patients were matched for: index year, age, gender, main indication at index, number of seasonal cycles within treatment period, baseline AR/asthma treatment prescriptions. Multiple regression analysis compared prescription data in AIT and non‐AIT groups as proxy for clinical status/disease progression.
Results: Up to 6 years of follow‐up, significantly more AIT (65.4%) vs non‐AIT (47.4%) patients were AR medication‐free; odds ratio (OR) [95% confidence interval (CI)]: 0.51 [(0.48‐0.54); P < 0.001] (28.6% covariate‐adjusted reduction vs non‐AIT; P < 0.001), and significantly more AIT (49.1%) vs non‐AIT (35.1%) patients were asthma medication‐free [OR (95% CI): 0.59 (0.55‐0.65); P < 0.001] (32% reduction vs non‐AIT; P < 0.001), or reduced existing asthma medication use (32% covariate‐adjusted reduction vs non‐AIT; P < 0.001). During treatment, new‐onset asthma risk was significantly reduced in the AIT vs non‐AIT group (OR: 0.83; P = 0.001).
Conclusions: Birch pollen AIT demonstrated real‐world benefits up to 6 years post‐treatment cessation through significantly reduced AR and asthma medication intake, and significantly decreased risk of new‐onset asthma medication use on‐treatment.
The German Cancer Consortium ('Deutsches Konsortium für Translationale Krebsforschung', DKTK) is a long-term cancer consortium, bringing together the German Cancer Research Center (DKFZ), Germany's largest life science research center, and the leading University Medical Center-based Comprehensive Cancer Centers (CCCs) at seven sites across Germany. DKTK was founded in 2012 following international peer review and has positioned itself since then as the leading network for translational cancer research in Germany. DKTK is long term funded by the German Ministry of Research and Education and the federal states of each DKTK partner site. DKTK acts at the interface between basic and clinical cancer research, one major focus being to generate suitable multisite cooperation structures and provide the basis for including higher numbers of patients and facilitate effective collaborative forward and reverse translational cancer research. The consortium addresses areas of high scientific and medical relevance and develops critical infrastructures, for example, for omics technologies, clinical and research big data exchange and analysis, imaging, and clinical grade drug manufacturing. Moreover, DKTK provides a very attractive environment for interdisciplinary and interinstitutional training and career development for clinician and medical scientists.
Alirocumab reduces total nonfatal cardiovascular and fatal events: The ODYSSEY OUTCOMES trial
(2018)
Background: The ODYSSEY OUTCOMES (Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab) trial compared alirocumab with placebo, added to high-intensity or maximum-tolerated statin treatment, after acute coronary syndrome (ACS) in 18,924 patients. Alirocumab reduced the first occurrence of the primary composite endpoint and was associated with fewer all-cause deaths.
Objectives: This pre-specified analysis determined the extent to which alirocumab reduced total (first and subsequent) nonfatal cardiovascular events and all-cause deaths in ODYSSEY OUTCOMES.
Methods: Hazard functions for total nonfatal cardiovascular events (myocardial infarction, stroke, ischemia-driven coronary revascularization, and hospitalization for unstable angina or heart failure) and death were jointly estimated, linked by a shared frailty accounting for patient risk heterogeneity and correlated within-patient nonfatal events. An association parameter also quantified the strength of the linkage between risk of nonfatal events and death. The model provides accurate relative estimates of nonfatal event risk if nonfatal events are associated with increased risk for death.
Results: With 3,064 first and 5,425 total events, 190 fewer first and 385 fewer total nonfatal cardiovascular events or deaths were observed with alirocumab compared with placebo. Alirocumab reduced total nonfatal cardiovascular events (hazard ratio: 0.87; 95% confidence interval: 0.82 to 0.93) and death (hazard ratio: 0.83; 95% confidence interval: 0.71 to 0.97) in the presence of a strong association between nonfatal and fatal event risk.
Conclusions: In patients with ACS, the total number of nonfatal cardiovascular events and deaths prevented with alirocumab was twice the number of first events prevented. Consequently, total event reduction is a more comprehensive metric to capture the totality of alirocumab clinical efficacy after ACS.
Aims: Of patients with atrial fibrillation (AF), approximately 10% undergo percutaneous coronary intervention (PCI). We studied the safety and efficacy of dual vs. triple antithrombotic therapy (DAT vs. TAT) in this population.
Methods and results: A systematic review and meta-analysis was conducted using PubMed, Embase, EBSCO, Cochrane database of systematic reviews, Web of Science, and relevant meeting abstracts for Phase 3, randomized trials that compared DAT vs. TAT in patients with AF following PCI. Four trials including 5317 patients were included, of whom 3039 (57%) received DAT. Compared with the TAT arm, Thrombolysis in Myocardial Infarction (TIMI) major or minor bleeding showed a reduction by 47% in the DAT arm [4.3% vs. 9.0%; hazard ratio (HR) 0.53, 95% credible interval (CrI) 0.36–0.85, I2 = 42.9%]. In addition, there was no difference in the trial-defined major adverse cardiac events (MACE) (10.4% vs. 10.0%, HR 0.85, 95% CrI 0.48–1.29, I2 = 58.4%), or in individual outcomes of all-cause mortality, cardiac death, myocardial infarction, stent thrombosis, or stroke between the two arms.
Conclusion: Compared with TAT, DAT shows a reduction in TIMI major or minor bleeding by 47% with comparable outcomes of MACE. Our findings support the concept that DAT may be a better option than TAT in many patients with AF following PCI.
The FIRE AND ICE Trial (ClinicalTrials.gov, identifier NCT01490814) was initiated in 2012 as a multicenter, randomized, head‐to‐head comparison of radiofrequency current (RFC) and cryoballoon catheter ablation for the treatment of patients with drug‐refractory symptomatic paroxysmal atrial fibrillation (AF). Six years on, it remains the largest, randomized comparison of safety and efficacy between 2 catheter ablation modalities used in the treatment of patients with AF. This landmark trial not only established noninferiority between cryoballoon and RFC ablation for pulmonary vein isolation (PVI) with regard to the study's efficacy and safety primary end points,1 but also, it evaluated secondary end points that were critical for a representative study interpretation. ...
Background: Alzheimer’s disease (AD) is the most common form of dementia, and it affects more women than men. Mitochondrial dysfunction (MD) plays a key role in AD, and it is detectable at an early stage of the degenerative process in peripheral tissues, such as peripheral mononuclear blood cells (PBMCs). However, whether these changes are also reflected in cerebral energy metabolism and whether sex-specific differences in mitochondrial function occur are not clear. Therefore, we estimated the correlation between mitochondrial function in PBMCs and brain energy metabolites and examined sex-specific differences in healthy participants to elucidate these issues.
Methods: The current pilot study included 9 male and 15 female healthy adults (mean age 30.8 ± 7.1 years). Respiration and activity of mitochondrial respiratory complexes were measured using a Clarke-electrode (Oxygraph-2k system), and adenosine triphosphate (ATP) levels were determined using a bioluminescence-based assay in isolated PBMCs. Citrate synthase activity as a mitochondrial marker was measured using a photometric assay. Concentrations of brain energy metabolites were quantified in the same individuals using 1H-magnetic resonance spectroscopy (MRS).
Results: We detected sex-associated differences in mitochondrial function. Mitochondrial complexes I, I+II, and IV and uncoupled respiration and electron transport system (ETS) capacity in PBMCs isolated from blood samples of females were significantly (p < 0.05; p < 0.01) higher compared to males. ATP levels in the PBMCs of female participants were approximately 10% higher compared to males. Citrate synthase (CS) activity, a marker of mitochondrial content, was significantly (p < 0.05) higher in females compared to males. Sex-associated differences were also found for brain metabolites. The N-acetylaspartate (NAA) concentration was significantly higher in female participants compared to males in targeted regions. This difference was observed in white matter (WM) and an area with a high percentage (> 50%) of gray matter (GM) (p < 0.05; p < 0.01). The effect sizes indicated a strong influence of sex on these parameters. Sex-associated differences were found in PBMCs and brain, but the determined parameters were not significantly correlated.
Conclusions: Our study revealed sex-associated differences in mitochondrial function in healthy participants. The underlying mechanisms must be elucidated in more detail, but our study suggests that mitochondrial function in PBMCs is a feasible surrogate marker to detect differences in mitochondrial function and energy metabolism in humans and it underscores the necessity of sex-specific approaches in therapies that target mitochondrial dysfunction.
Background: Myelofibrosis (MF) is a life-shortening complication of myeloproliferative neoplasms associated with ineffective hematopoiesis, splenomegaly, and progressive bone marrow (BM) fibrosis. The oral Janus kinase (JAK) 1/JAK2 inhibitor ruxolitinib has been shown to improve splenomegaly, symptom burden, and overall survival in patients with intermediate-2 or high-risk MF compared with placebo or best available therapy (BAT).
Methods: The effects of ruxolitinib therapy for up to 66 months on BM morphology in 68 patients with advanced MF with variable BM fibrosis grade were compared with those in 192 matching patients treated with BAT. Available trephine biopsies underwent independent, blinded review by three hematopathologists for consensus-based adjudication of grades for reticulin fibrosis, collagen deposition, and osteosclerosis.
Results: Ruxolitinib treatment versus BAT was associated with greater odds of BM fibrosis improvement or stabilization and decreased odds of BM fibrosis worsening based on changes from baseline in reticulin fibrosis grade. Generally, these changes were accompanied by a sustained higher level of individual spleen size reduction and regression of leukoerythroblastosis. Patients with more advanced baseline fibrosis showed lower spleen size response.
Conclusions: The finding that long-term ruxolitinib therapy may reverse or markedly delay BM fibrosis progression in advanced MF suggests that sustained JAK inhibition may be disease-modifying.
Trial registration: INCB18424-251, ClinicalTrials.gov identifier NCT00509899.
Objectives: The authors sought to evaluate the performance of the Ranger paclitaxel-coated balloon versus uncoated balloon angioplasty for femoropopliteal lesions at 12 months.
Background: Drug-coated balloons (DCBs) are a promising endovascular treatment option for peripheral artery disease of the femoropopliteal segment, and each unique device requires dedicated clinical study.
Methods: The prospective, randomized RANGER SFA (Comparison of the Ranger™ Paclitaxel-Coated PTA Balloon Catheter and Uncoated PTA Balloons in Femoropopliteal Arteries) study (NCT02013193) enrolled 105 patients with symptomatic lower limb ischemia (Rutherford category 2 to 4) and stenotic lesions in the nonstented femoropopliteal segment at 10 European centers. Seventy-one patients (mean age 68 ± 8 years, n = 53 men) were enrolled in the Ranger DCB arm, and 34 patients (mean age 67 ± 9 years, n = 23 men) were assigned to the control group. Twelve-month analysis included patency, safety, and clinical outcomes and quality-of-life assessments.
Results: The DCB group had a greater primary patency rate at 12 months (Kaplan-Meier estimate 86.4% vs. 56.5%), with a significantly longer time to patency failure (log-rank p < 0.001). The estimated freedom from target lesion revascularization rate was 91.2% in the DCB group and 69.9% in the control group at 12 months, with a significantly longer time to reintervention (p = 0.010). No target limb amputations or device-related deaths occurred in either group.
Conclusions: Twelve-month results show that patency was maintained longer after Ranger DCB treatment than after conventional balloon angioplasty, and this result was associated with a low revascularization rate and good clinical outcomes.
Incorporation of doxorubicin in different polymer nanoparticles and their anti-cancer activity
(2018)
Nanoparticles are under investigation as carrier systems for anti-cancer drugs. They have been shown to accumulate in cancer tissues through the enhanced permeability and retention (EPR) effect, to reduce toxicity to non-target tissues, and to protect drugs from preliminary inactivation. However, nanoparticle preparations are not commonly compared for their anti-cancer effects at the cellular level. Here, we prepared doxorubicin-loaded nanoparticles based on poly(lactic-co-glycolic acid) (PLGA), polylactic acid (PLA), and PEGylated PLGA (PLGA-PEG) by solvent displacement and emulsion diffusion approaches. The resulting nanoparticles covered a size range between 73 and 246 nm. PLGA-PEG nanoparticle preparation by solvent displacement resulted in the smallest nanoparticles. In PLGA nanoparticles, the drug load could be optimised using solvent displacement at pH7 reaching 53 µg doxorubicin/mg nanoparticle. In addition, these PLGA nanoparticles displayed sustained doxorubicin release kinetics compared to the more burst-like kinetics of the other preparations. In neuroblastoma cells, doxorubicin-loaded PLGA-PEG nanoparticles (presumably due to their small size) and PLGA nanoparticles prepared by solvent displacement at pH7 (presumably due to their high drug load and superior drug release kinetics) exerted the strongest anti-cancer effects. In conclusion, doxorubicin-loaded nanoparticles made by different methods from different materials displayed substantial discrepancies in their anti-cancer activity at the cellular level. Optimised preparation methods resulted in PLGA nanoparticles characterised by increased drug load, controlled drug release, and high anti-cancer efficacy. The design of drug-loaded nanoparticles with optimised anti-cancer activity at the cellular level is an important step in the development of improved nanoparticle preparations for anti-cancer therapy.
Environmental stability and infectivity of hepatitis C virus (HCV) in different human body fluids
(2018)
Background: Hepatitis C virus (HCV) is a hepatotropic, blood-borne virus, but in up to one-third of infections of the transmission route remained unidentified. Viral genome copies of HCV have been identified in several body fluids, however, non-parental transmission upon exposure to contaminated body fluids seems to be rare. Several body fluids, e.g., tears and saliva, are renowned for their antimicrobial and antiviral properties, nevertheless, HCV stability has never been systematically analyzed in those fluids.
Methods: We used state of the art infectious HCV cell culture techniques to investigate the stability of HCV in different body fluids to estimate the potential risk of transmission via patient body fluid material. In addition, we mimicked a potential contamination of HCV in tear fluid and analyzed which impact commercially available contact lens solutions might have in such a scenario.
Results: We could demonstrate that HCV remains infectious over several days in body fluids like tears, saliva, semen, and cerebrospinal fluid. Only hydrogen-peroxide contact lens solutions were able to efficiently inactivate HCV in a suspension test.
Conclusion: These results indicate that HCV, once it is present in various body fluids of infected patients, remains infective and could potentially contribute to transmission upon direct contact.
BACKGROUND & AIMS: Proton pump inhibitors (PPIs) are commonly prescribed to treat acid-related disorders. Some direct-acting antiviral regimens for chronic hepatitis C virus (HCV) infection have reduced efficacy in patients taking concomitant acid-reducing agents, including PPIs, due to interactions between drugs. We analyzed data from 9 multicenter, phase 2 and 3 trials to determine the efficacy and pharmacokinetics of an HCV therapeutic regimen comprising glecaprevir and pibrentasvir (glecaprevir/pibrentasvir) in patients taking concomitant acid-reducing agents.
METHODS: We analyzed data from 2369 patients infected with HCV genotypes 1-6 and compensated liver disease treated with an all-oral regimen of glecaprevir/pibrentasvir for 8-16 weeks. We compared efficacy and pharmacokinetics among patients receiving at least 1 dose of an acid-reducing agent (a PPI, an H2 blocker, or antacid). High-dose PPI was defined as daily dose greater than 20 mg omeprazole dose equivalent. The objectives were to evaluate rate of sustained virologic response 12 weeks post-treatment (SVR12) and to assess steady-state glecaprevir and pibrentasvir exposures in patients on acid-reducing agents.
RESULTS: Of the 401 patients (17%) who reported use of acid-reducing agents, 263 took PPIs (11%; 109 patients took a high-dose PPI and 154 patients took a low-dose PPI). Rates of SVR12 were 97.0% among patients who used acid-reducing agents and 97.5% among those not using acid-reducing agents (P = .6). An SVR12 was achieved in 96.3% taking a high-dose PPI and 97.4% taking a low-dose PPI, with no virologic failures in those receiving a high-dose PPI (P = .7). Glecaprevir, but not pibrentasvir, bioavailability was affected; its exposure decreased by 41% in patients taking a high-dose PPI.
CONCLUSIONS: In an analysis of data from 9 clinical trials, we observed a high rate of SVR12 (approximately 97%) among patients treated with glecaprevir/pibrentasvir for HCV infection-even among patients taking concomitant ARA or high-dose PPI. This was despite decreased glecaprevir exposures in patients when on high-dose PPIs. ClinicalTrials.gov numbers, NCT02243280 (SURVEYOR-I), NCT02243293 (SURVEYOR-II), NCT02604017 (ENDURANCE-1), NCT02640482 (ENDURANCE-2), NCT02640157 (ENDURANCE-3), NCT02636595 (ENDURANCE-4), NCT02642432 (EXPEDITION-1), NCT02651194 (EXPEDITION-4), NCT02446717 (MAGELLAN-I).
Developments in managing CF continue to drive dramatic improvements in survival. As newborn screening rolls-out across Europe, CF centres are increasingly caring for cohorts of patients who have minimal lung disease on diagnosis. With the introduction of mutation-specific therapies and the prospect of truly personalised medicine, patients have the potential to enjoy good quality of life in adulthood with ever-increasing life expectancy. The landmark Standards of Care published in 2005 set out what high quality CF care is and how it can be delivered throughout Europe. This underwent a fundamental re-write in 2014, resulting in three documents; center framework, quality management and best practice guidelines. This document is a revision of the latter, updating standards for best practice in key aspects of CF care, in the context of a fast-moving and dynamic field.
In continuing to give a broad overview of the standards expected for newborn screening, diagnosis, preventative treatment of lung disease, nutrition, complications, transplant/end of life care and psychological support, this consensus on best practice is expected to prove useful to clinical teams both in countries where CF care is developing and those with established CF centres. The document is an ECFS product and endorsed by the CF Network in ERN LUNG and CF Europe.
Background: Prospective memory is the ability to recall intended actions or events at the right time or in the right context. While cannabis is known to impair prospective memory, the acute effect of cocaine is unknown. In addition, it is not clear whether changes in prospective memory represent specific alterations in memory processing or result from more general effects on cognition that spread across multiple domains such as arousal and attention.
Aims: The main objective of the study was, therefore, to determine whether drug-induced changes in prospective memory are memory specific or associated with more general drug-induced changes in attention and arousal.
Methods: A placebo-controlled, three-way, cross-over study including 15 regular poly-drug users was set up to test the influence of oral cocaine (300 mg) and vaporised cannabis (300+150 ‘booster’ µg/kg bodyweight) on an event-based prospective memory task. Attentional performance was assessed using a divided attention task and subjective arousal was assessed with the Profile of Mood States questionnaire.
Results: Results showed that cocaine enhanced prospective memory, attention and arousal. Mean performance of prospective memory and attention, as well as levels of arousal were lowest during treatment with cannabis as compared with placebo and cocaine as evinced by a significantly increased trend across treatment conditions. Prospective memory performance was only weakly positively associated to measures of attention and arousal.
Conclusion: Together, these results indicate that cocaine enhancement of prospective memory performance cannot be fully explained by parallel changes in arousal and attention levels, and is likely to represent a direct change in the neural network underlying prospective memory.
Autophagy is a cytosolic quality control process that recognizes substrates through receptor‐mediated mechanisms. Procollagens, the most abundant gene products in Metazoa, are synthesized in the endoplasmic reticulum (ER), and a fraction that fails to attain the native structure is cleared by autophagy. However, how autophagy selectively recognizes misfolded procollagens in the ER lumen is still unknown. We performed siRNA interference, CRISPR‐Cas9 or knockout‐mediated gene deletion of candidate autophagy and ER proteins in collagen producing cells. We found that the ER‐resident lectin chaperone Calnexin (CANX) and the ER‐phagy receptor FAM134B are required for autophagy‐mediated quality control of endogenous procollagens. Mechanistically, CANX acts as co‐receptor that recognizes ER luminal misfolded procollagens and interacts with the ER‐phagy receptor FAM134B. In turn, FAM134B binds the autophagosome membrane‐associated protein LC3 and delivers a portion of ER containing both CANX and procollagen to the lysosome for degradation. Thus, a crosstalk between the ER quality control machinery and the autophagy pathway selectively disposes of proteasome‐resistant misfolded clients from the ER.